TOP TEN perturbations for 1481_at (Homo sapiens)
Organism: Homo sapiens
Gene: 1481_at
Selected probe(set): 204580_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 1481_at (204580_at) across 6674 perturbations tested by GENEVESTIGATOR:
Langerhans cell histiocytosis study 1 / normal plasmocytoid dendritic cell sample
Relative Expression (log2-ratio):9.405166Number of Samples:7 / 3
Experimental | Langerhans cell histiocytosis study 1 |
Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity. | |
Control | normal plasmocytoid dendritic cell sample |
Normal plasmocytoid dendritic cells were isolated from peripheral blood of healthy adult donors. Plasmocytoid dendritic cells were defined as HLA-DR+ / CD45RAhi / CD11c- / BDCA2+ population. |
Langerhans cell histiocytosis study 1 / normal myeloid dendritic cell sample
Relative Expression (log2-ratio):9.300008Number of Samples:7 / 3
Experimental | Langerhans cell histiocytosis study 1 |
Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity. | |
Control | normal myeloid dendritic cell sample |
Normal myeloid dendritic cells were isolated from peripheral blood of healthy adult donors. Myeloid dendritic cells were defined as HLA-DR+ / CD11c + / BDCA1+ / BDCA3- population. |
IL-4; GM-CSF study 1 (intermediate) / untreated monocyte sample
Relative Expression (log2-ratio):8.703003Number of Samples:7 / 12
Experimental | IL-4; GM-CSF study 1 (intermediate) |
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 24 hours. | |
Control | untreated monocyte sample |
Freshly isolated human monocytes from healthy donors. |
human AB serum study 1 (late) / IL-4; GM-CSF study 1 (late)
Relative Expression (log2-ratio):-8.093055Number of Samples:3 / 6
Experimental | human AB serum study 1 (late) |
Monocytes, cultured in RPMI medium containing 10% human AB serum (HS) instead of FBS, and 500 U/ml IL-4 and 800 U/ml GM-CSF for 5 days. Cytokine treatment was repeated at day 3. | |
Control | IL-4; GM-CSF study 1 (late) |
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 5 days. Cytokine treatment was repeated at day 3. |
IL-4; GM-CSF study 1 (late) / untreated monocyte sample
Relative Expression (log2-ratio):7.8208103Number of Samples:6 / 12
Experimental | IL-4; GM-CSF study 1 (late) |
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 5 days. Cytokine treatment was repeated at day 3. | |
Control | untreated monocyte sample |
Freshly isolated human monocytes from healthy donors. |
diphenylcyclopropenone study 1 (late) / diphenylcyclopropenone study 1 (early)
Relative Expression (log2-ratio):-7.4677978Number of Samples:6 / 10
Experimental | diphenylcyclopropenone study 1 (late) |
Skin biopsy samples of healthy volunteers exposed to diphenylcyclopropenone (diphencyprone; DPCP) for 4 to 8 months. ATC code:--- | |
Control | diphenylcyclopropenone study 1 (early) |
Skin biopsy samples of healthy volunteers exposed to diphenylcyclopropenone (diphencyprone; DPCP) for 3 days. ATC code:--- |
glioma study 17 (small cell glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):6.9143453Number of Samples:2 / 3
Experimental | glioma study 17 (small cell glioblastoma; A2B5+) |
Oligodendrocyte progenitor cells (OPC) isolated from high grade small cell glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 56 ± 3 years old males. | |
Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
atopic dermatitis study 21 (lesional; epidermis) / normal epidermis tissue
Relative Expression (log2-ratio):6.7752423Number of Samples:5 / 10
Experimental | atopic dermatitis study 21 (lesional; epidermis) |
Lesional epidermal samples isolated from patient with moderate-to-severe chronic atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
Control | normal epidermis tissue |
Epidermal samples isolated from healthy subjects by laser capture microdissection. |
expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)
Relative Expression (log2-ratio):-6.7301617Number of Samples:2 / 2
Experimental | expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) |
Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary. | |
Control | expO ovary cancer study 1 (dysgerminoma; metastatic) |
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary. |
atopic dermatitis study 21 (lesional; dermis) / normal dermis tissue
Relative Expression (log2-ratio):6.6973124Number of Samples:5 / 6
Experimental | atopic dermatitis study 21 (lesional; dermis) |
Lesional dermal samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
Control | normal dermis tissue |
Dermal samples isolated from healthy subjects by laser capture microdissection. |